Evaluation of an Interventional Module to Assist Physicians Introducing ACP to Cancer Patients

June 16, 2024 updated by: National Taiwan University Hospital

National Taiwan University Hospital,Taiwan (R.O.C)

Evaluation of an Interventional module to assist physicians introducing ACP to cancer patients

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Investigators hypothesize that compared to ACP brochure alone, educational module plus ACP brochure is effective in assisting the physicians to introduce ACP to the patients and completion of AD documentation

Study Type

Interventional

Enrollment (Actual)

384

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Taiwan
      • Taipei, Taiwan
        • Nation Taiwan University Hospital
      • Taipei county, Taiwan
        • National Taiwan University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

"Inclusion Criteria" and "Exclusion Criteria"

Inclusion Criteria

  1. Older than 20-years-old
  2. Diagnosed with cancer
  3. Have not signed any form of AD or DNR

Exclusion Criteria

  1. Under 20-years-old
  2. Can not speak or listen, difficult communication
  3. Signed AD or DNR

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group A
Group A had watching educational module plus ACP brochure
Other: For interventional module
Using vedio to assist physicians introducing advance care planning to cancer patients
Active Comparator: Group B
Group B ACP brochure only
Other: For interventional module
Using vedio to assist physicians introducing advance care planning to cancer patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sign DNR (Do-Not-Resuscitate)
Time Frame: 3 month
After intervention cancer patients willing sing DNR
3 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Completion AD(Advance directive) documentation
Time Frame: 3 month
After intervention cancer patients completion of a new AD documentation
3 month

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Explain and predict health behaviors(Sign DNR / Completion AD)
Time Frame: 3 month
To evaluate factors that might hinder patient willingness to sign DNR / complete AD documentation by applying the The Transtheoretical Model (TTM).
3 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Taiwan University Hospital

Investigators

  • Principal Investigator: Shao-Yi Cheng Shao-Yi, PHD, Shao-Yi Cheng

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 6, 2021

Primary Completion (Actual)

September 20, 2023

Study Completion (Actual)

December 20, 2023

Study Registration Dates

First Submitted

June 29, 2021

First Submitted That Met QC Criteria

July 9, 2021

First Posted (Actual)

July 21, 2021

Study Record Updates

Last Update Posted (Actual)

June 18, 2024

Last Update Submitted That Met QC Criteria

June 16, 2024

Last Verified

June 1, 2024

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 201912238RINA

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer Patients

Clinical Trials on For interventional module

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe